Saturday 17 October 2026
Export BMRN’s income statement to Excel — free account
BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
54.68
1.37
−2.44%
Follow BMRN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
32.65 | 29.21 | 110.17 | 130.66 | 0.00 | 18.58 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 8 | 6 | 8 | 4 | 4 | 6 | 6 | 4 | 4 |
P/S ratio |
3.54 | 4.38 | 7.61 | 8.89 | 8.75 | 8.52 | 8.88 | 10.11 | 12.09 | 12.76 |
Altman Z-Score |
5.67 | 6.68 | 6.38 | 7.14 | 5.96 | 5.93 | 5.83 | 6.32 | 5.25 | 5.94 |
P/FCF ratio |
15.90 | 25.73 | 356.59 | 126.21 | 87.18 | 1,056.63 | 0.00 | 298.03 | 697.39 | 0.00 |
Altman Z″-Score (non-manufacturers) |
7.43 | 7.30 | 4.34 | 4.72 | 3.87 | 4.02 | 2.16 | 2.97 | 2.41 | 1.34 |
Beneish M-Score |
(2.49) | (2.44) | (2.14) | (2.33) | (2.93) | (1.55) | (2.39) | (2.26) | (2.58) | (2.74) |
P/Operating CF |
114.39 | 67.29 | 670.13 | 2,746.77 | 1,444.99 | (1,184.60) | 263.99 | 305.36 | 1,086.50 | (67,848.34) |
P/B ratio |
1.87 | 2.21 | 3.72 | 4.05 | 3.79 | 3.86 | 4.85 | 5.08 | 5.65 | 5.15 |
Price to Tangible BV |
2.01 | 2.40 | 4.13 | 4.58 | 4.39 | 4.54 | 6.13 | 6.62 | 7.58 | 7.07 |
EV/Sales |
3.39 | 4.36 | 7.62 | 8.80 | 8.79 | 8.53 | 8.94 | 10.19 | 11.92 | 12.66 |
EV/EBITDA |
22.57 | 21.74 | 65.60 | 69.33 | 526.05 | 254.84 | 5,358.31 | 0.00 | 205.36 | 0.00 |
EV/Operating CF |
13.20 | 21.72 | 115.73 | 104.84 | 53.29 | 185.98 | 315.61 | 752.03 | (1,787.89) | (62.07) |
EV/FCF |
15.24 | 25.63 | 356.84 | 124.87 | 87.58 | 1,058.08 | (168.97) | 300.41 | 687.66 | (40.24) |
Quick Ratio |
3.25 | 2.96 | 1.45 | 2.98 | 2.54 | 3.07 | 1.21 | 2.73 | 2.03 | 2.29 |
Current Ratio |
5.21 | 5.33 | 2.51 | 4.67 | 4.16 | 4.76 | 2.08 | 3.93 | 2.70 | 3.24 |
Net Debt/EBITDA |
(1.99) | (0.95) | 0.05 | (0.75) | 2.44 | 0.35 | 33.17 | 9.23 | (2.91) | 0.15 |
Debt/Assets |
7.86% | 8.52% | 15.89% | 17.15% | 18.14% | 18.59% | 18.08% | 18.76% | 25.35% | 16.98% |
Debt/Equity |
0.10 | 0.11 | 0.22 | 0.24 | 0.26 | 0.26 | 0.27 | 0.28 | 0.42 | 0.25 |
Asset Turnover |
0.44 | 0.41 | 0.37 | 0.34 | 0.31 | 0.35 | 0.37 | 0.33 | 0.30 | 0.29 |
Operating CF/Net income |
2.37 | 1.34 | 0.95 | 1.24 | (4.75) | 0.10 | (2.02) | (0.26) | 0.07 | 0.36 |
Capex/Depreciation |
(1.48) | (0.99) | (1.13) | (0.27) | (1.05) | (0.67) | (1.34) | (0.99) | (0.82) | (1.51) |
Interest Coverage |
37.57 | 38.23 | 10.72 | 10.08 | (5.37) | (1.48) | (4.28) | (2.83) | (0.34) | (20.34) |
| 5.94% | 8.05% | 3.51% | 3.19% | (1.53%) | 23.63% | (0.78%) | (2.67%) | (4.20%) | (24.39%) | |
| 4.79% | 6.17% | 2.54% | 2.29% | (1.08%) | 16.21% | (0.52%) | (1.70%) | (2.70%) | (16.26%) | |
ROIC |
5.00% | 5.92% | 2.34% | 2.28% | (1.19%) | (0.66%) | (1.95%) | (2.84%) | (0.36%) | (18.88%) |
Return on Tangible Assets |
8.41% | 11.64% | 5.89% | 4.37% | (2.32%) | 29.63% | (1.18%) | (3.11%) | (5.12%) | (35.38%) |
Average Days of Receivables |
102.91 | 84.48 | 95.61 | 80.33 | 73.82 | 87.96 | 80.84 | 83.87 | 72.62 | 70.36 |
Research and Development Expense of Revenue |
28.62% | 26.18% | 30.87% | 30.99% | 34.06% | 33.76% | 41.96% | 46.70% | 46.49% | 59.27% |
Selling, General and Administrative Expense of Revenue |
35.79% | 35.36% | 36.89% | 39.28% | 41.13% | 39.65% | 39.96% | 40.53% | 42.20% | 42.67% |
Intangible Assets out of Total Assets |
0.05 | 0.06 | 0.07 | 0.08 | 0.10 | 0.10 | 0.14 | 0.16 | 0.15 | 0.19 |
Share Based Compensation of Revenue |
5.63% | 7.06% | 8.56% | 9.37% | 10.68% | 10.20% | 9.38% | 9.98% | 10.68% | 12.06% |
Graham Net Nets |
0.21 | 0.15 | 0.06 | 0.05 | 0.03 | 0.04 | 0.02 | 0.04 | 0.02 | 0.01 |
Graham Number |
36.05 | 38.82 | 22.98 | 20.75 | 0.00 | 49.11 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
3.06% | 3.42% | 0.91% | 0.77% | (0.40%) | 5.38% | (0.17%) | (0.50%) | (0.73%) | (4.58%) |
Free Cash Flow Yield |
6.29% | 3.89% | 0.28% | 0.79% | 1.15% | 0.09% | (0.60%) | 0.34% | 0.14% | (2.47%) |
Revenue per Share |
16.80 | 15.02 | 12.88 | 11.31 | 10.10 | 10.29 | 9.52 | 8.42 | 7.53 | 6.73 |
Operating CF per Share |
4.32 | 3.01 | 0.85 | 0.95 | 1.67 | 0.47 | 0.27 | 0.11 | (0.05) | (1.37) |
Capex per Share |
(0.58) | (0.46) | (0.57) | (0.15) | (0.65) | (0.39) | (0.77) | (0.53) | (0.43) | (0.89) |
Free Cash Flow per Share |
3.74 | 2.55 | 0.28 | 0.80 | 1.01 | 0.08 | (0.50) | (0.42) | (0.48) | (2.27) |
Cash per Share |
8.14 | 5.99 | 5.72 | 6.97 | 5.54 | 5.89 | 4.21 | 6.12 | 8.00 | 4.76 |
Shareholders Equity per Share |
31.74 | 29.77 | 26.36 | 24.85 | 23.33 | 22.71 | 17.44 | 16.76 | 16.10 | 16.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
31.74 | 29.77 | 26.36 | 24.85 | 23.33 | 22.71 | 17.44 | 16.76 | 16.10 | 16.67 |
Free Cash Flow |
717.02 | 485.42 | 51.65 | 147.69 | 185.31 | 15.01 | (90.14) | (74.41) | (82.98) | (376.22) |
Working Capital |
3,194.46 | 2,625.44 | 1,779.06 | 2,162.57 | 1,727.89 | 1,849.67 | 1,009.64 | 1,532.97 | 1,390.63 | 982.48 |
Capital Expenditures |
(110.97) | (87.42) | (107.61) | (28.21) | (119.22) | (70.36) | (138.41) | (94.62) | (74.22) | (148.38) |
Net Current Asset Value |
2,446.47 | 1,901.48 | 1,066.03 | 979.54 | 535.28 | 600.20 | 374.49 | 597.03 | 382.68 | 164.38 |
EV/EBIT |
26.69 | 25.70 | 99.21 | 114.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.01 | 0.06 | 0.04 | 0.08 | 0.06 | 0.06 | 0.13 |
Price to Operating Income |
27.84 | 25.80 | 99.14 | 115.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.12 |
Cash ROIC |
8.70% | 6.57% | 0.73% | 2.11% | 2.91% | 0.24% | (1.91%) | (1.52%) | (1.54%) | (8.87%) |
Accounts Receivable Turnover |
4.11 | 4.41 | 4.42 | 5.02 | 4.49 | 4.51 | 4.73 | 4.94 | 5.51 | 5.87 |
Accounts Payable Turnover |
1.05 | 0.90 | 0.85 | 0.94 | 0.95 | 0.99 | 0.71 | 0.75 | 0.63 | 0.55 |
Inventory Turnover |
0.57 | 0.50 | 0.53 | 0.60 | 0.64 | 0.76 | 0.59 | 0.63 | 0.58 | 0.67 |
Average Days of Payables |
386.16 | 381.83 | 468.65 | 415.75 | 386.53 | 342.91 | 579.41 | 506.28 | 606.74 | 645.14 |
Days of Inventory on Hand |
660.81 | 775.41 | 759.54 | 648.76 | 602.50 | 486.33 | 690.75 | 614.62 | 718.23 | 618.36 |
Average Receivables |
784.37 | 647.12 | 547.51 | 417.36 | 410.88 | 412.88 | 360.02 | 302.00 | 238.32 | 190.12 |
Average Payables |
683.01 | 645.07 | 628.05 | 535.61 | 495.41 | 531.58 | 503.96 | 419.61 | 386.21 | 381.51 |
Average Inventory |
1,265.77 | 1,169.92 | 1,000.63 | 835.38 | 737.61 | 689.41 | 605.57 | 503.32 | 415.45 | 313.40 |
Average Assets |
7,291.48 | 6,915.27 | 6,608.34 | 6,189.92 | 5,926.40 | 5,269.03 | 4,558.58 | 4,530.13 | 4,328.41 | 3,876.53 |
Average Common Equity |
5,872.49 | 5,304.77 | 4,777.35 | 4,434.41 | 4,185.84 | 3,614.19 | 3,045.16 | 2,888.30 | 2,787.47 | 2,583.56 |
Columns are period end dates